Pharmacy Benefits Management Services Home

Because of the concern for liver injury developing in patients receiving lomitapide, the risk of using lomitapide in patients without a diagnosis of HoFH (e.g., heterozygous hypercholesterolemia, statin intolerant patients) is unfavorable and therefore, lomitapide treatment should be restricted to patients with HoFH. Introduction. 1-2 ................
................